Paraneoplastik hiperkalsemi, özellikle ileri evre solid organ malignitelerinde (meme kanseri, böbrek kanseri, akciğer kanseri) ve multipl miyelomda yaygındır ve kötü prognoz ile ilişkilidir. Kronik lenfositik lösemide paraneoplastik hiperkalsemi nadiren görülür. Düşük insidansı nedeniyle literatürde hiperkalseminin prognoza ve tedavisine etkisi hakkında yeterli veri bulunmamaktadır. Kronik lenfositik lösemi tanısı ile takip edilen ve semptomatik malign hiperkalsemi gelişen 68 yaşındaki erkek hastada nadir görülen bu durumu bildirdik. İbrutinibin kronik lenfositik lösemiye bağlı hiperkalsemi kontrolünde etkili olduğu sonucuna vardık.
Anahtar Kelimeler: kronik lenfositik lösemi, hiperkalsemi, ibrutinibParaneoplastic hypercalcemia is common, especially in advanced stage solid organ malignancies (breast cancer, renal cancer, lung cancer) and multiple myeloma, and is associated with poor prognosis. Paraneoplastic hypercalcemia is rarely observed in chronic lymphocytic leukemia. Due to its low incidence, there is not enough data in the literature about the effect of hypercalcemia on prognosis and its treatment. We reported this rare condition that a 68-year-old male who was followed up with a diagnosis of chronic lymphocytic leukemia and developed symptomatic malignant hypercalcemia. We concluded that ibrutinib was effective in the control of hypercalcemia due to chronic lymphocytic leukemia.
Keywords: leukemia, lymphocytic, chronic, B-cell, hypercalcemia, ibrutinib